https://scholars.lib.ntu.edu.tw/handle/123456789/494985
標題: | 140PD: LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations | 作者: | Park K Tan E.-H Zhang L Hirsh V O'Byrne K Boyer M CHIH-HSIN YANG Mok T Kim M Paz-Ares L. |
公開日期: | 2016 | 出版社: | Elsevier Inc | 卷: | 11 | 期: | 4 | 起(迄)頁: | S117-S118 | 來源出版物: | Journal of Thoracic Oncology | URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85037604373&doi=10.1016%2fS1556-0864%2816%2930250-7&partnerID=40&md5=44f300d7099cc9c659bd825642f4ab3a https://scholars.lib.ntu.edu.tw/handle/123456789/494985 |
ISSN: | 1556-0864 | DOI: | 10.1016/S1556-0864(16)30250-7 | SDG/關鍵字: | afatinib; alanine aminotransferase; epidermal growth factor receptor; gefitinib; acne; advanced cancer; alanine aminotransferase blood level; Article; Asian; brain metastasis; controlled study; diarrhea; drug efficacy; drug response; drug safety; drug treatment failure; drug withdrawal; EGFR gene; female; gene deletion; gene mutation; human; major clinical study; male; non small cell lung cancer; open study; overall survival; phase 2 clinical trial; priority journal; progression free survival; prospective study; randomized controlled trial; rash; side effect; tumor volume |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。